Form 4: Celldex Therapeutics Executive Granted 85,000 Stock Options Under Equity Incentive Plan

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, Inc., was granted 85,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Summary

• Elizabeth Crowley, Senior Vice President and Chief Product Development Officer (SR. VP & CPDO) of Celldex Therapeutics, Inc. (CLDX), was granted 85,000 incentive stock options.
• The options have an exercise price of $19.53 per share.
• The transaction date for this grant was June 5, 2025.
• These options were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
• The vesting schedule dictates that 25% of the options will vest on June 5, 2026, with the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters.
• The options have an expiration date of June 5, 2035.
• Following this transaction, Ms. Crowley beneficially owns 85,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine filing, the grant of options aligns executive incentives with shareholder value and is a standard, healthy practice for executive retention and motivation. There are no negative surprises.

Positives

• The grant of incentive stock options aligns the interests of a key executive, Elizabeth Crowley, with those of shareholders, as her compensation becomes tied to the company's stock performance.
• This type of equity grant is a standard component of executive compensation packages, indicating a commitment to retaining and incentivizing senior leadership.
• The options were granted under the company's established 2021 Omnibus Equity Incentive Plan, reflecting a structured approach to long-term incentives.

Negatives

• No direct negatives are apparent from this routine insider compensation filing.

Risks

• The value of the granted options is subject to the future performance of Celldex Therapeutics' stock, meaning the options may not become 'in-the-money' if the stock price does not exceed the exercise price of $19.53.
• Dilution risk for existing shareholders could arise if a significant number of options are exercised, although this specific grant of 85,000 shares is relatively small in the context of a publicly traded company's total outstanding shares.

Future Outlook

The vesting schedule of the granted options extends through June 2029, indicating a long-term incentive structure for the executive and a future potential increase in shares outstanding as options are exercised.

Industry Context

In the biotechnology and pharmaceutical sectors, executive compensation often includes significant equity components like stock options. This practice is common to incentivize long-term value creation, given the extended development timelines and high-risk, high-reward nature of drug discovery and commercialization. The grant to a Chief Product Development Officer is particularly relevant as product development is central to value creation in this industry.

Comparison to Industry Standards

• The grant of incentive stock options is a standard practice for executive compensation across the biotechnology and pharmaceutical industries, aligning executive interests with shareholder value.
• The vesting schedule of 25% after one year and quarterly thereafter over three years (total four years) is a common structure designed to encourage long-term retention and performance, comparable to practices at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals for similar executive roles.
• The specific number of options (85,000) and exercise price ($19.53) would need to be evaluated against the executive's overall compensation package, company size, and peer group compensation data to determine if it is above, below, or in line with industry benchmarks. Without this broader context, a direct quantitative comparison is not feasible from this filing alone.

Corporate Governance

Related Party Transactions

• The grant of incentive stock options to Elizabeth Crowley, a Senior Vice President and Chief Product Development Officer, constitutes a related party transaction between the company and one of its key executives as part of her compensation.

Stakeholder Impact

• Shareholders: The grant aligns the executive's financial interests with the company's stock performance, potentially leading to more focused efforts on increasing shareholder value. However, future exercise of options could lead to minor dilution.
• Employees: This grant is specific to a senior executive; however, it reflects the company's overall approach to executive compensation and incentive structures.
• Management: The grant provides a significant long-term incentive for Elizabeth Crowley, encouraging her continued dedication and performance in her role.

Next Steps

• The options will begin to vest on June 5, 2026, with subsequent quarterly vesting periods over the following three years.
• Elizabeth Crowley may choose to exercise these options at any point after they vest and before their expiration date of June 5, 2035, subject to company policy and blackout periods.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Incentive Stock Option, Executive Compensation, Insider Transaction, Equity Grant, Biotechnology, Pharmaceuticals